FDA approves Takeda’s orexin receptor agonist for narcolepsy, opening new drug class

The FDA has granted approval to Takeda's novel narcolepsy medication, the first orexin receptor agonist to receive clearance.

The twice‑daily pill, marketed as Orzeyful, is indicated for narcolepsy type 1, a disorder caused by a deficiency of orexin neurons that leads to excessive daytime sleepiness and muscle weakness.

Current therapies, including stimulants and sodium oxybate, carry risks of misuse and often leave patients still feeling sleepy, making the new option appealing.

Scientists see the approval as validation of the orexin receptor agonist class, which is also being investigated for a broader range of neurologic conditions.